Filing Flows › Travere Therapeutics (TVTX) › License and collaboration revenue revenue
Travere Therapeutics (TVTX) License and collaboration revenue revenue by quarter
Travere Therapeutics' License and collaboration revenue revenue was $4.4M in Q3 2026 (third quarter 2026), -47% from Q2 2026. Over the last 7 quarters it ranged from $2.7M (Q1 2026) to $51.7M (Q3 2025).
| Quarter | License and collaboration revenue revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $4.4M | -47% | -92% |
| Q2 2026 | $8.2M | +204% | -58% |
| Q1 2026 | $2.7M | -12% | -54% |
| Q4 2025 | $3.1M | -94% | — |
| Q3 2025 | $51.7M | +164% | — |
| Q2 2025 | $19.6M | +234% | — |
| Q1 2025 | $5.9M | — | — |
Q3 2026 at a glance
Travere Therapeutics, Q3 2026: revenue $225M (+36% year over year), operating margin -30.3%, net loss $52.3M, operating cash flow $98.2M. The chart follows the revenue to costs, profit and cash.
Questions
What is Travere Therapeutics' License and collaboration revenue revenue?
Travere Therapeutics' License and collaboration revenue revenue was $4.4M in Q3 2026 (third quarter 2026), -47% from Q2 2026.
How has Travere Therapeutics' License and collaboration revenue revenue changed?
Over the last 7 quarters it ranged from $2.7M (Q1 2026) to $51.7M (Q3 2025).